Notice: This company has been marked as potentially delisted and may not be actively trading. ArQule (ARQL) News Today Add Compare Share Share Headlines Stock Analysis All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Merck Sharp & Dohme Corp.'s Net WorthMarch 22, 2024 | benzinga.comASCO Live Blog: SaturdayJune 30, 2023 | thestreet.com2023 Fibroblast Growth Factor Receptor 2 Inhibitor Market Share and Growth Rate Forecast for 2030May 5, 2023 | marketwatch.comWelcome to My Portfolio - Link your brokers or add lotsApril 3, 2023 | finance.yahoo.com40+ Key Companies Actively Working in the Marginal Zone Lymphoma Pipeline Segment | DelveInsight - GlobeNewswireSeptember 21, 2022 | globenewswire.comForm SC 13E3 Stealth BioTherapeutics Filed by: Stealth BioTherapeutics Corp - StreetInsider.comAugust 21, 2022 | streetinsider.comMerus Stock: Precision Oncology Pioneer Executes In The Clinic (NASDAQ:MRUS) - Seeking AlphaJune 30, 2022 | seekingalpha.comAptose Reports Results for the First Quarter 2022 - GuruFocus.comJune 18, 2022 | gurufocus.comAptose Biosciences Inc. (APTO) CEO Dr. William G. Rice on Q1 2022 Results - Earnings Call Transcript - Seeking AlphaMay 9, 2022 | seekingalpha.comRENEWABLE ENERGY GROUP, INC. : Other Events (form 8-K) - Marketscreener.comMay 9, 2022 | marketscreener.comAptose Reports Results for the First Quarter 2022 - Financial PostMay 9, 2022 | financialpost.comForm DEF 14A Deciphera Pharmaceutical For: Jun 23 - StreetInsider.comApril 26, 2022 | streetinsider.comBasilea reports preclinical data on oncology drug candidates BAL0891, derazantinib and lisavanbulin at AACR Annual Meeting - GlobeNewswireApril 13, 2022 | globenewswire.comAPTOSE BIOSCIENCES INC. : Change in Directors or Principal Officers, Other Events, Financial Statements and Exhibits (form 8-K) - Marketscreener.comApril 11, 2022 | marketscreener.comAptose Announces Executive Management Changes - StreetInsider.comApril 8, 2022 | streetinsider.comWest Pharmaceutical Services : Names President and CEO Eric M. Green as Chair of the Board - Form 8-K - marketscreener.comMarch 1, 2022 | marketscreener.comWest Names President and CEO Eric M. Green as Chair of the Board - PRNewswireFebruary 28, 2022 | prnewswire.comBasilea to become a leading anti-infectives company backed - GlobeNewswireFebruary 15, 2022 | globenewswire.comHeartFlow Appoints Timothy Barabe to its Board of Directors - StreetInsider.comJanuary 20, 2022 | streetinsider.comHeartFlow Appoints Timothy Barabe to its Board of Directors - Yahoo FinanceJanuary 18, 2022 | finance.yahoo.comBasilea reports on portfolio progress made in 2021 - GlobeNewswireJanuary 6, 2022 | globenewswire.comCuris Adds Three New Executives to Management Team Strengthening Medical Affairs, Clinical Development and Clinical Operations - marketscreener.comJanuary 3, 2022 | marketscreener.comSAVA Stock: 8 Things to Know as Cassava Sciences Rockets Higher - InvestorPlaceNovember 2, 2021 | investorplace.comBasilea presents preclinical data on synergy between derazantinib and paclitaxel in gastric tumor models at ANE Conference - Yahoo FinanceOctober 11, 2021 | finance.yahoo.comEnlivex Therapeutics : NOTICE OF ANNUAL AND EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS ON (Form 6-K) - Marketscreener.comSeptember 30, 2021 | marketscreener.comForm 6-K Enlivex Therapeutics For: Sep 30 - StreetInsider.comSeptember 30, 2021 | streetinsider.comMerck & Co., Inc. (MRK) Management Presents at European Society for Medical Oncology Virtual Congress 2021 (Transcript) - Seeking AlphaSeptember 21, 2021 | seekingalpha.comBasilea presents full safety and efficacy data set on derazantinib in patients with FGFR2 fusion-positive iCCA at ESMO congress - StreetInsider.comSeptember 18, 2021 | streetinsider.comBasilea presents full safety and efficacy data set on derazantinib in patients with FGFR2 fusion-positive iCCA at ESMO congress - Yahoo Finance UKSeptember 17, 2021 | uk.finance.yahoo.comBasilea presents full safety and efficacy data set on derazantinib in patients with FGFR2 fusion-positive iCCA at ESMO congress - Yahoo FinanceSeptember 17, 2021 | finance.yahoo.comBasilea presents full safety and efficacy data set on derazantinib in patients with FGFR2 fusion-positive - BenzingaSeptember 17, 2021 | benzinga.comMerck & Co., Inc. (MRK) CEO Robert Davis Presents at Morgan Stanley 19th Annual Global Healthcare Conference (Transcript) - Seeking AlphaSeptember 13, 2021 | seekingalpha.comInfinity Pharma Names Robert Ilaria As CMO And Brian Schwartz To Board - Quick Facts - NasdaqSeptember 7, 2021 | nasdaq.comInfinity Pharma (INFI) Appoints Robert Ilaria as Chief Medical Officer; Brian Schwartz to its Board - StreetInsider.comSeptember 7, 2021 | streetinsider.comBasilea reports strong financial results for half-year 2021 - GlobeNewswireAugust 17, 2021 | globenewswire.comPress Release : Basilea reports strong financial -3- - Marketscreener.comAugust 17, 2021 | marketscreener.com Get ArQule News Delivered to You Automatically Sign up to receive the latest news and ratings for ARQL and its competitors with MarketBeat's FREE daily newsletter. Email Address 625,000% Gain (Ad)Imagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz. >> Dive into the Workshop Here ARQL Media Mentions By Week ARQL Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ARQL News Sentiment▼0.000.45▲Average Medical News Sentiment ARQL News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ARQL Articles This Week▼00▲ARQL Articles Average Week Get ArQule News Delivered to You Automatically Sign up to receive the latest news and ratings for ARQL and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Exelixis News Today Repligen News Today Halozyme Therapeutics News Today Ionis Pharmaceuticals News Today Alkermes News Today Madrigal Pharmaceuticals News Today Amicus Therapeutics News Today Geron News Today Myriad Genetics News Today Ligand Pharmaceuticals News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ARQL) was last updated on 11/2/2024 by MarketBeat.com Staff From Our PartnersMusk warns humanity: “Obsolete”The 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | Sponsored625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredThe centerpiece of Trump’s crypto’s masterplan …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin...Weiss Ratings | SponsoredHow Will You Survive A Post Election Retirement Heist?The clock is ticking, and your life savings are in an extremely vulnerable position. We are a few days away...American Hartford Gold Group | SponsoredBlackrock’s Sending THIS Crypto Higher on PurposeIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ArQule, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ArQule With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
